Clinical Trial Update: Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating AZD1236 for cystic fibrosis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• AZD1236

Snippet

Sponsor: AstraZeneca | Conditions: Cystic Fibrosis | Phase 2 | Status: WITHDRAWN